The archive · Bio & Materials · Product decision · 2019–2026
Prime Medicine proves prime editing in humans, then hands CGD off for bigger markets
Prime Medicine bets prime editing can fix disease mutations, proves it in two CGD patients, then pivots the ultra-rare program outward.
Prime Medicine
What the business is
A clinical-stage gene-editing biotech building one-time therapies from prime editing, a search-and-replace editor that corrects a mutation without cutting both DNA strands.
Starting capital：Came out of stealth in 2021 with US$315M; Bristol Myers Squibb paid US$110M upfront in 2024 for a CAR-T collaboration with up to US$3.5B in milestones; Prime held US$190M in cash at the end of 2024.
How it started
David Liu, who co-invented prime editing at the Broad Institute, co-founded Prime Medicine to turn the technology into therapies; the company emerged from stealth in 2021 with US$315M and set out to correct disease-causing mutations in liver, lung and blood diseases.
What happened
Its first clinical program, PM359, edits a patient's own blood stem cells ex vivo to repair the two-base-pair deletion in NCF1 behind p47phox CGD, then returns them after conditioning. On May 19, 2025 the company reported first-patient data: 58% DHR-positive neutrophils by Day 15 and 66% by Day 30 versus a 20% clinical-benefit threshold, with neutrophil engraftment on Day 14 and platelets on Day 19 — roughly twice as fast as the median reported for approved gene-editing therapies — and no PM359-related serious adverse events. The same day it announced it would not independently advance CGD: 25% of staff were laid off, CEO Keith Gottesdiener resigned with CFO Allan Reine taking over, and the stock fell 19% to $1.28. On December 7, 2025 the New England Journal of Medicine published two-patient data: 69% and 83% DHR positivity by Day 30, stable for at least six months, with no new CGD-related complications.
How it ended up
Still running as a public biotech focused on Wilson's Disease, Alpha-1 Antitrypsin Deficiency and its BMS CAR-T collaboration. On June 22, 2026 the FDA granted PM359 Regenerative Medicine Advanced Therapy designation, joining Fast Track, Orphan Drug and Rare Pediatric Disease designations, as the company works toward a Biologics License Application.
Background
Prime Medicine emerged from stealth in 2021 with US$315M to commercialize prime editing, a search-and-replace genome editor invented in David Liu's Broad Institute lab that corrects a pathogenic mutation without cutting both DNA strands. Its founding bet was that precision of that kind — not blunt double-strand breaks — would become the platform for a new class of one-time genetic therapies.
To prove the platform, the company chose p47phox chronic granulomatous disease, an ultra-rare inherited immune deficiency where a single two-base-pair deletion in NCF1 cripples the neutrophils that kill bacteria and fungi. PM359 edits a patient's own blood stem cells ex vivo and returns them after conditioning; FDA orphan drug and rare pediatric disease designations smoothed the path to a multinational first-in-human Phase 1/2 trial.
On May 19, 2025, first-patient data showed 58% and 66% DHR-positive neutrophils by Days 15 and 30 — far above the 20% clinical-benefit threshold — engraftment roughly twice as fast as approved gene-editing therapies, and no PM359-related serious adverse events. The same day Prime said it would stop funding CGD itself: a 25% workforce cut, a CEO transition to Allan Reine, and a stock drop of 19% to $1.28. On December 7, 2025 the New England Journal of Medicine published both patients' results: 69% and 83% DHR positivity by Day 30, durable for at least six months.
The strategic read was blunt: prime editing had been validated in humans, but the ultra-rare indication could not sustain a company of Prime's scale, so the program's future was handed to external partners while the company refocused on larger genetic diseases in the liver and lung and its Bristol Myers Squibb CAR-T collaboration. On June 22, 2026, the FDA granted PM359 Regenerative Medicine Advanced Therapy designation — alongside Fast Track, Orphan Drug and Rare Pediatric Disease status — as the company works toward a Biologics License Application.
What has to be true
- CGD is genetically simple and functionally measurable: one well-understood mutation and a direct neutrophil-function readout let a two-patient study produce unambiguous proof.
- Prime editing avoids double-strand breaks, and May 2025 data showed engraftment twice as fast as approved gene-editing therapies: neutrophils Day 14 and platelets Day 19 versus Days 27 and 35.
- The milestone is hard and dated: NEJM-published results of 69% and 83% DHR-positive neutrophils by Day 30 versus a 20% threshold, durable for six-plus months with no related serious adverse events.
- The follow-through was strategic: after clinical proof, Prime pivoted its capital to larger liver targets (Wilson's Disease, AATD) while FDA designations kept PM359 moving toward approval.
What can be applied
A proof market should prove, not pay: CGD validated prime editing in humans, but was too small to sustain the company — Prime Medicine handed it off and targeted bigger diseases.
Aftermath
As of June 2026 Prime Medicine is a public company (Nasdaq: PRME) focused on Wilson's Disease, Alpha-1 Antitrypsin Deficiency and the Bristol Myers Squibb CAR-T collaboration. PM359 holds RMAT, Fast Track, Orphan Drug and Rare Pediatric Disease designations as the company works toward a Biologics License Application, and its first-in-human trial continues follow-up. The open question is whether the platform's clinical proof converts into approved products in larger indications before cash runs out.
Sources
- Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
- Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staff
- Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
- Prime Editing Clinical Results Published for the First Time Ever
- Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card